- BVT 2733
-
- $37.00 / 5mg
-
2024-11-18
- CAS:376640-41-4
- Min. Order:
- Purity: 99.64%
- Supply Ability: 10g
|
| | BVT 2733 Basic information |
| Product Name: | BVT 2733 | | Synonyms: | 3-chloro-2-methyl-N-(4-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)thiazol-2-yl)benzenesulfonamide;BVT 2733(BVT.2733);BENZENESULFONAMIDE, 3-CHLORO-2-METHYL-N-[4-[2-(4-METHYL-1-PIPERAZINYL)-2-OXOETHYL]-2-THIAZOLYL]-;3-CHLORO-2-METHYL-N-[4-[2-(4-METHYLPIPERAZIN-1-YL)-2-OXOETHYL]-1,3-THIAZOL-2-YL]BENZENESULFONAMIDE;BVT2733, >98%;BVT.2733 >=98% (HPLC);HFD,CIA,BVT-2733,J774.1,arthritis,macrophage,collagen,inhibit,BVT2733,BVT 2733,disease,adipocyte,Inhibitor,obesity;3-chloro-2-methyl-N-[4-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-2-thiazolyl]-benzenesulfonamide | | CAS: | 376640-41-4 | | MF: | C17H21ClN4O3S2 | | MW: | 428.96 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 376640-41-4.mol |  |
| | BVT 2733 Chemical Properties |
| Boiling point | 636.9±65.0 °C(Predicted) | | density | 1.427±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | ≥42.9 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH | | form | solid | | pka | 6.36±0.10(Predicted) | | color | Off-white to pink |
| | BVT 2733 Usage And Synthesis |
| Uses | BVT 2733 is a selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1. | | Biological Activity | ki: 1 μm using 11-dehydrocorticosterone as substratebvt 2733 is a novel, small molecule, non-steroidal, and selective inhibitor of 11beta-hydroxysteroid dehydrogenase type 1 (11β-hsd1).11β-hsd1 has been reported to alter glucocorticoid hormone action in target tissues for insulin action and is suggested to play a key role in glucose homeostasis. | | in vitro | bvt 2733 was identified as a novel type 1 selective inhibitor of murine 11β-hsd1 (ki 1 μmol/l), which did not inhibit mouse 11β-hsd type 2 at a concentration as high as 200 μmol/l (corresponding to a ki >33 μmol/l). therefore, the selectivity of bvt 2733 for the 11β-hsd type 1 enzyme over the type 2 enzyme was estimated to be at least 30-fold based on the ki values [1]. | | in vivo | in mice, bvt 2733 treatment could lower hepatic pepck and glucose-6-phosphatase mrna, serum insulin and blood glucose concentrations compared with vehicle treated mice. in contrast, hepatic 11beta-hydroxysteroid dehydrogenase type 1 mrna, liver function marker enzyme expression including alanine aminotransferase, aspartate aminotransferase and alkaline phosphatases, body weight as well as daily food intake were not changed by the treatment of bvt 2733 [1]. | | references | [1] alberts p,engblom l,edling n,forsgren m,klingstrm g,larsson c,rnquist-nii y,ohman b,abrahmsén l. selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. diabetologia.2002 nov;45(11):1528-32. |
| | BVT 2733 Preparation Products And Raw materials |
|